Evidence map›Paper›PMID 37817647›Full record

Observational studyInternational journal of urology : official journal of the Japanese Urological Association2024

Efficacy and safety of intravesical dimethyl sulfoxide treatment for patients with refractory Hunner-type interstitial cystitis: Real-world data postofficial approval in Japan.

Yoshiyuki Akiyama, Aya Niimi, Akira Nomiya, Satoru Taguchi, Yuta Yamada, Yusuke Sato, Taketo Kawai, Daisuke Yamada, Haruki Kume, Yukio Homma

Open access · hybridAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in International journal of urology : official journal of the Japanese Urological Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Animal Models of Hunner-Type Interstitial Cystitis.International journal of urology : official journal of the Japanese Urological Association · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Yoshiyuki AkiyamaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Aya NiimiDepartment of Urology, New Tokyo Hospital, Matsudo, Chiba, Japan.
Akira NomiyaDepartment of Urology, Kanto Rosai Hospital, Kawasaki, Kanagawa, Japan.
Satoru TaguchiDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yuta YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yusuke SatoDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-6239-6050
Taketo KawaiDepartment of Urology, Teikyo University School of Medicine, Tokyo, Japan.ORCID 0000-0002-7279-2874
Daisuke YamadaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Yukio HommaDepartment of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPKansai Rosai Hospital · JPKyorin University · JPNew Tokyo Hospital · JPTeikyo University · JP

Funding

Japan Society for the Promotion of Science (JSPS) 22K16788Ministry of Health, Labour and Welfare 18060798
6 · The paper itself

Abstract

objectivesTo examine real-world data regarding intravesical dimethyl sulfoxide (DMSO) therapy after official approval as a treatment for Hunner-type interstitial cystitis (HIC) in Japan.

methodsThis single institution, retrospective observational study was conducted between 2021 and 2022 to evaluate the outcomes of 30 patients with refractory HIC who received intravesical DMSO therapy according to the approved standardized regimen: administration of DMSO every 2 weeks for a total of 12 weeks. Treatment outcomes were evaluated using a 7-graded global response assessment scale, O'Leary and Sant's symptom and problem indices (OSSI/OSPI), the overactive bladder symptom score (OABSS), an 11-point pain intensity numerical rating scale, quality of life (QOL) score, and frequency volume chart variables. Related complications were also documented.

resultsThe response rates at 2, 4, 6, 8, 10, and 12 weeks were 36.7%, 43.3%, 53.3%, 60.0%, 70.0%, and 70.0%, respectively. Compared with baseline, OSSI/OSPI, pain intensity, urinary frequency, and the QOL score improved significantly from 4 weeks of treatment. The OABSS score and functional bladder capacity also showed a tendency toward moderate improvement, but the difference was not significant. The mean duration of symptom relapse after termination of treatment was 6.4 ± 3.9 months. No patients discontinued treatment due to adverse events, although acute bladder irritation during infusion was noted in 21 patients (70%), which disappeared within 3 days.

conclusionsThis study verifies the safety, moderately durable efficacy, and tolerability of the standard intravesical treatment with DMSO for HIC in Japan.

Indexed as

Cystitis, InterstitialAdministration, IntravesicalDimethyl SulfoxideHumansJapanQuality of LifeTreatment OutcomeDimethyl Sulfoxidebladder pain syndromedimethyl sulfoxideDMSOHunnerIC/BPSinterstitial cystitis

Identifiers

PMID37817647
PMCPMC11524091
OpenAlexW4387515955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.